Application of Nuclear Imaging Probes in PD-L1 Immunotherapy of Tumor / 肿瘤防治研究
Cancer Research on Prevention and Treatment
; (12): 1123-1128, 2021.
Article
en Zh
| WPRIM
| ID: wpr-988467
Biblioteca responsable:
WPRO
ABSTRACT
Immunotherapy strategies of targeting PD-1 and its ligand PD-L1 are widely administered in varied types of cancer. Patient benefitting from PD-L1 targeted immunotherapy mainly depends on the expression level of PD-L1 in tumor tissues. Currently, the expression level of PD-L1 is primarily detected through the invasive method of biopsy in clinic, which is severely limited by the temporal and spatial heterogeneity of PD-L1 expression. Nuclear medicine probe can realize the noninvasive as well as in vivo detection of PD-L1 at the molecular level, which has important clinical significance for the guidance of patient screening and the prediction of patient's response to immunotherapy. This article reviews PD-L1 targeting nuclear imaging probes and their applications in tumor PD-L1 imaging.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Cancer Research on Prevention and Treatment
Año:
2021
Tipo del documento:
Article